STELARA® Phase 3 UNIFI Study Ulcerative Colitis

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=ELm-8mtBphs

Returning guest, Dr. William Sandborn, Chief of the Division of Gastroenterology at UC San Diego Health, discusses recent data from the Phase 3 UNIFI study evaluating the safety and efficacy of Janssen's STELARA® (ustekinumab) as a maintenance therapy in patients with moderately to severely active ulcerative colitis who previously failed biologic or conventional therapy. The long-term extension study out to two years, includes an abstract showing the effect of treatment on stool frequency and rectal bleeding. These data were presented at the 2020 American College of Gastroenterology (ACG) Annual Meeting. • #STELARA #Ustekinumab #UlcerativeColitis • Visit our website • www.healtprofessionalradio.com.au • Follow us on our social media channels • Facebook: / hprfm • Twitter: / healthproradio • Google+: https://plus.google.com/+HealthProfes... • Pinterest: / healthprora. . • Linkedin: / heal. . • Instagram: / healthprofe. . • Subscribe to our podcast channels • Soundcloud: / healthprofessi. . • Itunes: https://itunes.apple.com/nz/podcast/h... • Support us on Patreon • / hpr

#############################

New on site